BYD shares dip as Q3 earnings disappoint

More in Business

• A pharma giant is moving past one patent cliff — but another is already looming

  Novartis is heavily banking on its investigational multiple sclerosis therapy remibrutinib to generate billions in revenue as impending patent expirations threaten major revenue streams. Although the Swiss pharmaceutical firm weathered recent generic competition for its heart drug Entresto, it faces an estimated $18 billion revenue risk when blockbuster treatments Kisqali and Kesimpta lose patent exclusivity around 2032.

  3 min read
• SC hears Reliance's ONGC gas dispute appeal

  India's apex judicial body has stepped in to examine a long-running energy dispute involving deepwater assets in the Krishna-Godavari basin. The litigation centers on government allegations that commercial operators extracted and sold substantial volumes of migrated natural gas without authorization. The final verdict will determine whether the private energy consortium must satisfy massive financial claims stemming from accusations of unjust enrichment and fraud.

  1 min read
• Oracle says it isn’t worried about $165 billion Project Jupiter, but investors are

  Executives at Oracle Cloud Infrastructure are treating the massive New Mexico facility as routine business despite mounting hurdles that have pushed company shares down over 30% this year. The development is designed to support OpenAI, but severe utility delays have pressured its construction debt and triggered a force majeure notice. Because lease terms obligate the tech firm to secure power and cover debt liabilities, the setback poses significant financial exposure.

  2 min read